Company Background ChemGenex Pharmaceuticals Limited (ChemGenex) is an integrated biopharmaceutical development company with specialize in the discovery and the development of oncology drugs. As of June 30, 2010, ChemGenex Pharmaceuticals Inc. and ChemGenex Europe SAS were 100% owned by ChemGenex Pharmaceuticals Limited. ChemGenex focuses on developing targeted medicines for the treatment of cancer by identifying and targeting the genetic components of a range of cancer types. The Company has two molecules in clinical development and has progressed its lead compound, omacetaxine, to regulatory submission in Europe and the United States. The Company has submitted Omacetaxine to United States and European regulators for approval in chronic myeloid leukemia (CML) patients who have failed the tyrosine kinase inhibitor (TKI) imatinib and have the T315I point mutation. ChemGenex's other development stage molecule Quinamed, has completed phase IIa clinical trials in a range of solid cancers. ..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.